pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['kn671', 'pembro']
#asco23 ca kn671: neoadj pembro+chemo(placebo) x 4-&gt;surgery-&gt;adj pembro(placebo) x 13
a.1-year efs (73% vs. 60%, hr 0.58)
b.pcr (18% vs. 4%) and mpr (30% vs. 11%)
c.82.1% of patients received in-study surgery best neoadj cycles &amp; adj tx role
more will be on 
Hematology/Medical Oncology Fellow @RoswellPark
Thoracic Oncology Researcher
Future Asst Professor @UW & @FredHutch
Retweet ≠ endorsement
Views are my own